申请人:EGIS GYÓGYSZERGYÁR ZRT
公开号:WO2015028828A1
公开(公告)日:2015-03-05
The invention relates to novel (1:1) salts of sorafenib and the hydrate and solvate forms thereof. More specifically the invention concerns: - the sorafenib hydrogen-bromide (1:1) monoacetonitrile solvate salt, - the sorafenib hydrogen-bromide (1:1) hemihydrate salt, - the sorafenib naphthalene-2-sulfonic acid (1:1) anhydrous (form I, II and III) salt, - the sorafenib naphthalene-2-sulfonic acid (1:1) monoethanol solvate salt. Moreover the invention relates to preparing the mentioned sorafenib salts, pharmaceutical compositions comprising them for the treatment of carcinoma.
本发明涉及索拉非尼的新型(1:1)盐及其水合物和溶剂化物形式。更具体地,本发明涉及:-索拉非尼氢溴酸(1:1)单乙腈溶剂盐,-索拉非尼氢溴酸(1:1)半水合盐,-索拉非尼萘酸-2-磺酸(1:1)无水物(I、II和III型)盐,-索拉非尼萘酸-2-磺酸(1:1)单乙醇溶剂盐。此外,本发明还涉及制备上述索拉非尼盐,以及包含它们的制药组合物,用于治疗癌症。